Akeso apparently disagreed with investors’ reactions after the Chinese biotech on 25 April provided an early release of preliminary overall survival (OS) data from an interim analysis of a high-stakes head-to-head Phase III trial of ivonescimab versus Keytruda (pembrolizumab) in non-small cell lung cancer (NSCLC).
Key Takeaways
- Akeso/Summit's ivonescimab has shown a preliminary overall survival hazard ratio of 0.777 in the head-to-head HARMONi-2 study versus Keytruda in NSCLC, with no p value disclosed.
While ivonescimab, Akeso’s bispecific anti-PD-1/VEGF antibody, clearly beat Merck & Co.’s PD-1-targeting blockbuster in a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?